AI assistant
NovoCure Ltd — Director's Dealing 2025
Jan 3, 2025
31949_dirs_2025-01-03_68fa553c-0350-47d1-af3d-de918b442b31.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2025-01-01
Reporting Person: Danziger Asaf (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Ordinary Shares | A | 412.00 | $14.748 | Acquired | 15640.00 | Direct |
| 2025-01-01 | Ordinary Shares | A | 400000.00 | $0.00 | Acquired | 415640.00 | Direct |
Footnotes
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024.
F3: Represents restricted share units that are scheduled to vest in equal installments on December 31, 2025 and December 31, 2026, subject to the reporting person's continued employment through such dates.